Literature DB >> 14579152

Glutaric aciduria type 1 and neonatal screening: time to proceed--with caution.

Andrea Superti-Furga1.   

Abstract

The new technology of tandem mass spectrometry is having a significant impact on the diagnostics of inborn metabolic errors. One of the most important aspects of this new technology is the possibility of recognising a whole class of disorders within a single analytical step. Shall this powerful technology be applied to the screening of newborn babies? Careful evaluation of every single disorder that could potentially be identified is needed. In the following, I will present some considerations that concern glutaric aciduria type 1 (MIM 231670; glutaryl-CoA dehydrogenase deficiency).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14579152     DOI: 10.1007/s00431-003-1344-2

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  34 in total

1.  Natural history of glutaric aciduria type 1.

Authors:  J Collins; J V Leonard
Journal:  Arch Dis Child       Date:  2000-07       Impact factor: 3.791

2.  Glutaric aciduria type 1: MR findings in two cases.

Authors:  N R Altman; M J Rovira; M Bauer
Journal:  AJNR Am J Neuroradiol       Date:  1991 Sep-Oct       Impact factor: 3.825

3.  Outcome of the first 3-years of a DNA-based neonatal screening program for glutaric acidemia type 1 in Manitoba and northwestern Ontario, Canada.

Authors:  C R Greenberg; A N Prasad; L A Dilling; J R G Thompson; J C Haworth; B Martin; P Wood-Steiman; L E Seargeant; B Seifert; F A Booth; C Prasad
Journal:  Mol Genet Metab       Date:  2002-01       Impact factor: 4.797

4.  Subdural hematoma and glutaric aciduria type 1.

Authors:  P Drigo; A B Burlina; P A Battistella
Journal:  Brain Dev       Date:  1993 Nov-Dec       Impact factor: 1.961

5.  Chronic treatment with glutaric acid induces partial tolerance to excitotoxicity in neuronal cultures from chick embryo telencephalons.

Authors:  Stefan Kölker; Jürgen G Okun; Barbara Ahlemeyer; Angela T S Wyse; Friederike Hörster; Moacir Wajner; Dirk Kohlmüller; Ertan Mayatepek; Josef Krieglstein; Georg F Hoffmann
Journal:  J Neurosci Res       Date:  2002-05-15       Impact factor: 4.164

6.  Children with bilateral temporal arachnoid cysts may have glutaric aciduria type 1 (GAT1); operation without knowing that may be harmful.

Authors:  V Lütcherath; P E Waaler; E Jellum; K Wester
Journal:  Acta Neurochir (Wien)       Date:  2000       Impact factor: 2.216

Review 7.  A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism.

Authors:  M J Thomason; J Lord; M D Bain; R A Chalmers; P Littlejohns; G M Addison; A H Wilcox; C A Seymour
Journal:  J Public Health Med       Date:  1998-09

8.  Macrocephaly, dystonia, and bilateral temporal arachnoid cysts: glutaric aciduria type 1.

Authors:  J F Martínez-Lage; C Casas; M A Fernández; A Puche; T Rodriguez Costa; M Poza
Journal:  Childs Nerv Syst       Date:  1994-04       Impact factor: 1.475

9.  [Macrocephaly as the initial manifestation of glutaryl-CoA-dehydrogenase deficiency (glutaric aciduria type I)].

Authors:  F K Trefz; G F Hoffmann; E Mayatepek; U Lichter-Konecki; J Weisser; A Otten; U Wendel; D Rating; H J Bremer
Journal:  Monatsschr Kinderheilkd       Date:  1991-11       Impact factor: 0.323

10.  CT and MR of the brain in the diagnosis of organic acidemias. Experiences from 107 patients.

Authors:  J Brismar; P T Ozand
Journal:  Brain Dev       Date:  1994-11       Impact factor: 1.961

View more
  2 in total

Review 1.  Neonatal screening for glutaryl-CoA dehydrogenase deficiency.

Authors:  M Lindner; S Kölker; A Schulze; E Christensen; C R Greenberg; G F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

2.  Outcome of three cases of untreated maternal glutaric aciduria type I.

Authors:  Paula Garcia; Esmeralda Martins; Luísa Diogo; Hugo Rocha; Ana Marcão; Eurico Gaspar; Margarida Almeida; Catarina Vaz; Isabel Soares; Clara Barbot; Laura Vilarinho
Journal:  Eur J Pediatr       Date:  2007-07-28       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.